Hope for early breast cancer: targeted drug may cut recurrence risk

NCT ID NCT03701334

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to receive either hormone therapy alone or hormone therapy plus ribociclib. The main goal is to see if the combination improves how long people stay free of invasive cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: ribociclib (a targeted cancer drug) plus endocrine therapy (hormone-blocking drugs)
What this could lead to: If successful, this could offer a new treatment option to lower the risk of breast cancer returning in people with early-stage hormone-sensitive breast cancer.
What could go wrong: This is a large phase 3 trial, but results are not yet final. Ribociclib can cause side effects like infections, liver issues, and heart rhythm changes, and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

5,101 people

The number who actually took part.

Started

Dec 2018

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Signed and dated Patient Informed Consent Form (PICF) obtained prior to any trial-specific screening procedure. 2. Patient is ≥ 18 years-old at the time of PICF signature. 3. Patient is female with known menopausal status at the time of randomization or initiation of adjuvant ET (whichever occurs earlier), or male. Postmenopausal status is defined as: * Patient underwent bilateral oophorectomy, or * Age ≥ 60 years, or * Age \< 60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression) and Follicle-stimulating hormone (FSH) and plasma estradiol are in the postmenopausal ranges per local normal ranges. * If taking tamoxifen or toremifene and age \<60 years, then FSH and plasma estradiol level in postmenopausal ranges. Notes * In women who are premenopausal at the beginning of adjuvant chemotherapy, amenorrhea is not a reliable indicator of menopausal status as ovarian function may still be intact or resume despite anovulation/amenorrhea. For these women with therapy-induced amenorrhea, serial measurements of FSH and/or estradiol per local clinical guidelines are required for determination of postmenopausal status. * All women who do not meet the criteria for postmenopausal status are considered premenopausal for the purpose of this trial. 4. Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis (i.e. date of the pathology report that confirmed the BC diagnosis) within 18 months prior to randomization. Patient with a multicentric and/or multifocal tumor is eligible if all histopathologically examined lesions meet the pathologic criteria in inclusion criteria 5 and 6. 5. Patient has breast cancer that is positive for ER and/or PgR according to the local laboratory as determined on the most recently analyzed tissue sample. 6. Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required to confirm the HER2-negative status (based on the most recently analyzed tissue sample tested by a local laboratory). 7. Patient (except those enrolled in China) has available archival tumor tissue from the surgical specimen, for submission to a central laboratory (Note: in patients that underwent neoadjuvant systemic therapy and had a pathologic complete response, archival tumor tissue at the time of the initial diagnosis or before the administration of neoadjuvant therapy is mandatory). 8. Patient, after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories: * Anatomic Stage Group III, or * Anatomic Stage Group IIB, or * Anatomic Stage Group IIA (subset) Notes: * For patients whose tumors are Anatomic Stage IIA, N0: * If Grade is 1 or unknown (Gx), patient is not eligible. * If Grade 2, the gene expression test results (by Oncotype DX, Prosigna/PAM50, MammaPrint or EndoPredict EPclin) or Ki67 levels should be used if obtained as per local practice (i.e. are not mandatory for the purpose of the trial). Results must be available at screening. * Patients that received neoadjuvant treatment must meet the above criteria (for stage, and if Stage IIA, N0, also for grade and Ki67 or gene expression test) in any presurgical staging/sample and/or in the surgical specimen. * Categorization into the AJCC 8th edition Anatomic Stage Groups requires determination of the T, N and M categories. ALND is the preferred method for axillary lymph node staging, however SLN dissection can be used to determine the N category in the following cases: * No metastasis in SLN (patient is considered as pN0). * Only micrometastasis in SLN (patient is considered as pN1mi). * Patients with T1-2 and no clinically-evident nodes prior to surgery, no neoadjuvant chemotherapy, at least one macrometastasis in 1 or 2 SLNs, no matted nodes or gross extranodal disease at the time of SLN dissection (patient is considered as pN1). In all other cases, ALND is required to determine the N category. 9. If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines, prior to screening. 10. If indicated, patient has completed adjuvant radiotherapy according to the institutional guidelines, prior to screening. 11. Patient has no contraindication for the adjuvant ET in the trial and is planned to be treated with ET for 5 years (since randomization date) or more. 12. Patient may have already received any standard neoadjuvant and/or adjuvant ET at the time of PICF signature, but randomization should occur within 12 months of the initial start date of ET. Ovarian suppression or short term ET for fertility preservation is not considered neoadjuvant/adjuvant ET. If patient was receiving tamoxifen or toremifene as adjuvant ET, a washout period of 5 half-lives (i.e. 35 days) prior to randomization is required (during that period patient can take AI). 13. Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 14. Patient has adequate bone marrow and organ function as defined by the following local laboratory values: * Absolute neutrophil count (ANC) ≥ 1.5 × 109/L * Platelets ≥ 100 × 109/L * Hemoglobin ≥ 9.0 g/dL * Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) formula * Alanine transaminase (ALT) \< 2.5 × Upper Limit Normal (ULN) * Aspartate transaminase (AST) \< 2.5 × ULN * Total serum bilirubin \< ULN; or total bilirubin ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN in patients with well documented Gilbert's Syndrome * International normalized ratio (INR) ≤ 1.5 (unless the patient is receiving anticoagulants and the INR is within the therapeutic range of intended use for that anticoagulant within 7 days prior to randomization) * Patient must have the following laboratory values within normal limits or corrected to within normal limits with supplements (the local laboratory value should be documented within normal limits after the correction) before randomization: * Potassium * Magnesium * Total Calcium (corrected for serum albumin) 15. Standard 12-lead ECG values assessed by a central laboratory, as: * QTcF interval (QT interval using Fridericia's correction) at screening \< 450 milliseconds (msec) * Resting heart rate 50-90 beats per minute (determined from the ECG) 16. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures. 17. Women of childbearing potential (CBP), defined as all women physiologically capable of becoming pregnant (see Inclusion Criterion #18 for additional information), must have confirmed negative serum pregnancy test (for β-hCG) within 14 days prior to randomization. 18. Women of CBP must be willing to use highly effective methods of contraception. Contraception must continue during the trial treatment and for 21 days after stopping the treatment. Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking trial treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. * Male partner sterilization (at least 6 months prior to randomization). For female patients on the trial the vasectomized male partner should be the sole partner for that patient. If vasectomy of the male partner is the highly effective method of contraception chosen, the success of the vasectomy should be medically confirmed according to local practice. * Placement of an intrauterine device (IUD). Notes: * Use of oral (estrogen and progesterone), transdermal, injected, implanted, hormone containing intrauterine system or any other hormonal method of contraception is not allowed in this trial. * Women are considered of CBP unless: they have had ≥ 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment she is considered not of CBP. * After the end of trial treatment, patients should use effective contraception according to local guidelines. Exclusion Criteria 1. Patient has received any CDK4/6 inhibitor. 2. Patient has received prior treatment with tamoxifen, raloxifene or AIs for reduction in risk ("chemoprevention") of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. Patient is concurrently using hormone replacement therapy. 3. Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin. 4. Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET (e.g. rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, and soy allergy). 5. Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery. 6. Patient is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET (see Inclusion Criterion #12). 7. Patient has had major surgery, chemotherapy or radiotherapy within 14 days prior to randomization. 8. Patient has not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies to a NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03 Grade ≤1 at day of randomization. Exceptions to this criterion: patients with any grade of alopecia, amenorrhea, grade 2 neuropathy are allowed to enter the trial or other toxicities not considered a safety risk for the patient as per Investigator's discretion, are allowed to enter the trial. 9. Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization. Note: Patients with adequately treated, basal or squamous cell skin carcinoma or curatively resected cervical cancer in situ are eligible. 10. Patient has known history of human immunodeficiency virus (HIV) infection (testing is not mandatory, unless required by local regulation). 11. Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (testing is not mandatory, unless required by local regulation). 12. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following: * History of documented myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft within 6 months prior to trial entry. * Documented cardiomyopathy. * Left Ventricular Ejection Fraction (LVEF) \< 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) (testing not mandatory) * Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: * Risk factors for Torsades de Pointes (TdP) including uncorrected hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia. * Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause TdP that cannot be discontinued or replaced by safe alternative medication (e.g. within 5 half-lives or 7 days prior to starting trial treatment). * Inability to determine the QTcF interval. * Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade Atrioventricular (AV) block (e.g. bifascicular block, Mobitz type II and third degree AV block). * Uncontrolled arterial hypertension with systolic blood pressure \> 160 mmHg. 13. Patient is currently receiving any of the following substances within 7 days before randomization: * Concomitant medications, herbal supplements, and/or fruits (e.g. grapefruit, pummellos, starfruit, Seville oranges) and their juices that are known as strong inhibitors or inducers of CYP3A4/5 * Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 14. Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting trial treatment, or has not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: a short duration (\<5 days) of systemic corticosteroids; any duration of topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local injections (e.g. intra-articular). 15. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the oral trial treatments (e.g. uncontrolled ulcerative diseases, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, or small bowel resection). 16. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver disease, active untreated or uncontrolled fungal, bacterial or viral infections, active infection requiring systemic anti-bacterial therapy, etc.) or limit life expectancy to ≤5 years. 17. Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s) (whichever is longer), or participation in any other type of medical research judged not to be scientifically or medically compatible with this trial. If the patient is enrolled or planned to be enrolled in another study that does not involve an investigational drug, the agreement of the Medical Monitor is required to establish eligibility. 18. Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early breast cancer

Contacts and locations

Locations

Baptist MD Anderson Cancer Center

Jacksonville, Florida, 32207, United States
Baylor Charles A Sammons Cancer Cnt

Dallas, Texas, 75246, United States
Cancer Care Associates Medical Grp

Redondo Beach, California, 90277, United States
Cancer Care Center

New Albany, Indiana, 47150, United States
Cancer Center of Kansas

Wichita, Kansas, 67214-3728, United States
Cancer Treatment Centers of America

Goodyear, Arizona, 85338, United States
Cancer Treatment Centers of America

Zion, Illinois, 60099, United States
Cancer Treatment Centers of America Eastern Regional Medical Center

Philadelphia, Pennsylvania, 19124, United States
Central Coast Medical Oncology Corporation

Santa Maria, California, 93454, United States
Comprehensive Blood and Cancer

Bakersfield, California, 93309, United States
Comprehensive Cancer Cntr Of Nevada

Henderson, Nevada, 89052, United States
Cone Health Cancer Center

Greensboro, North Carolina, 27403, United States
Ctr For Cancer And Blood Disorders

Fort Worth, Texas, 76104, United States
David C Pratt Cancer Center

St Louis, Missouri, 63141, United States
Eastern Connecticut Hematology and Oncology Associates

Norwich, Connecticut, 06360, United States
Encino Research Center

Encino, California, 91436, United States
Fairview Health Services

Maple Grove, Minnesota, 55369, United States
Florida Cancer Specialists

Fort Myers, Florida, 33901, United States
Florida Cancer Specialists

West Palm Beach, Florida, 33401, United States
Florida Cancer Specialists Pan

Tallahassee, Florida, 32308, United States
Florida Cancer Specialists-North

St. Petersburg, Florida, 33705, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
HCA Midwest Division

Kansas City, Missouri, 64132, United States
Holy Cross Hospital-Ft. Lauderdale

Fort Lauderdale, Florida, 33308, United States
Hospital of Central Connecticut

New Britain, Connecticut, 06052, United States
Kaiser Permanente NW Region

Clackamas, Oregon, 97015, United States
Lundquist Inst BioMed at Harbor

Torrance, California, 90509-2910, United States
MD Anderson Cancer Center University of Texas

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Cancer Institute

Hollywood, Florida, 33021, United States
Mercy Medical Center

Baltimore, Maryland, 21202, United States
Metro Minnesota CCOP

Saint Louis Park, Minnesota, 55416, United States
Norton Cancer Institute

Louisville, Kentucky, 40202, United States
Norwalk Hospital

Norwalk, Connecticut, 06856, United States
Novartis Investigative Site

Rosario, Santa Fe Province, S2000, Argentina
Novartis Investigative Site

Rosario, Sante Fe, S200KZE, Argentina
Novartis Investigative Site

San Miguel Tucuman, Tucumán Province, T4000IAK, Argentina
Novartis Investigative Site

Rio Negro, Viedma, 8500, Argentina
Novartis Investigative Site

CABA, C1419AHN, Argentina
Novartis Investigative Site

Córdoba, X5004FHP, Argentina
Novartis Investigative Site

La Rioja, 5300, Argentina
Novartis Investigative Site

San Salvador de Jujuy, 4600, Argentina
Novartis Investigative Site

Campbelltown, New South Wales, 2560, Australia
Novartis Investigative Site

Coffs Harbour, New South Wales, 2450, Australia
Novartis Investigative Site

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site

Kingswood, New South Wales, 2747, Australia
Novartis Investigative Site

Kogarah, New South Wales, 2217, Australia
Novartis Investigative Site

North Ryde, New South Wales, 2109, Australia
Novartis Investigative Site

St Leonards, New South Wales, 2065, Australia
Novartis Investigative Site

Wahroonga, New South Wales, 2076, Australia
Novartis Investigative Site

Westmead, New South Wales, 2145, Australia
Novartis Investigative Site

Auchenflower, Queensland, 4066, Australia
Novartis Investigative Site

Birtinya, Queensland, 4575, Australia
Novartis Investigative Site

Wooloongabba, Queensland, 4102, Australia
Novartis Investigative Site

Bedford Park, South Australia, 5041, Australia
Novartis Investigative Site

Bendigo, Victoria, 3550, Australia
Novartis Investigative Site

East Melbourne, Victoria, 3002, Australia
Novartis Investigative Site

Epping, Victoria, 3076, Australia
Novartis Investigative Site

Fitzroy, Victoria, 3065, Australia
Novartis Investigative Site

Franston, Victoria, 3199, Australia
Novartis Investigative Site

Heidelberg, Victoria, 3084, Australia
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Shepparton, Victoria, 3630, Australia
Novartis Investigative Site

Murdoch, Western Australia, 6150, Australia
Novartis Investigative Site

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site

Liverpool, 2170, Australia
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Linz, 4020, Austria
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Hasselt, Limburg, 3500, Belgium
Novartis Investigative Site

Leuven, Vlaams Brabant, 3000, Belgium
Novartis Investigative Site

Brussels, 1000, Belgium
Novartis Investigative Site

Brussels, 1200, Belgium
Novartis Investigative Site

Charleroi, 6000, Belgium
Novartis Investigative Site

Edegem, 2650, Belgium
Novartis Investigative Site

Jette, 1090, Belgium
Novartis Investigative Site

Libramont, 6800, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Namur, 5000, Belgium
Novartis Investigative Site

Wilrijk, 2610, Belgium
Novartis Investigative Site

Yvoir, 5530, Belgium
Novartis Investigative Site

Londrina, Paraná, 86015-520, Brazil
Novartis Investigative Site

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90050-170, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90560-030, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
Novartis Investigative Site

Barretos, São Paulo, 14784-400, Brazil
Novartis Investigative Site

Santo André, São Paulo, 09060-650, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 01317-000, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 04014-002, Brazil
Novartis Investigative Site

Caxias do Sul, 95070-560, Brazil
Novartis Investigative Site

Passo Fundo, 99010-080, Brazil
Novartis Investigative Site

Piracicaba, 13419-155, Brazil
Novartis Investigative Site

Recife, 50040-000, Brazil
Novartis Investigative Site

Rio de Janeiro, 20560-120, Brazil
Novartis Investigative Site

Salvador, 41810-570, Brazil
Novartis Investigative Site

São Paulo, 01255-000, Brazil
Novartis Investigative Site

Calgary, Alberta, T2N 4N2, Canada
Novartis Investigative Site

Edmonton, Alberta, T6G 1Z2, Canada
Novartis Investigative Site

Kelowna, British Columbia, V1Y 5L3, Canada
Novartis Investigative Site

North Vancouver, British Columbia, V7L 2L7, Canada
Novartis Investigative Site

Surrey, British Columbia, V3V 1Z2, Canada
Novartis Investigative Site

Vancouver, British Columbia, V5Z 4E6, Canada
Novartis Investigative Site

Halifax, Nova Scotia, B3H 2Y9, Canada
Novartis Investigative Site

Greater Sudbury, Ontario, P3E 5J1, Canada
Novartis Investigative Site

Kitchener, Ontario, N2G 1G3, Canada
Novartis Investigative Site

London, Ontario, N6A 5W9, Canada
Novartis Investigative Site

Newmarket, Ontario, J7Y 2P9, Canada
Novartis Investigative Site

Oshawa, Ontario, L1G 2B9, Canada
Novartis Investigative Site

Sault Ste. Marie, Ontario, P6B 0A8, Canada
Novartis Investigative Site

Toronto, Ontario, M4N 3M5, Canada
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Windsor, Ontario, N8W 2X3, Canada
Novartis Investigative Site

Fleurimont, Quebec, J1H 5N4, Canada
Novartis Investigative Site

Greenfield Park, Quebec, J4V 2H1, Canada
Novartis Investigative Site

Montreal, Quebec, H2W 1T8, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site

Québec, Quebec, G1S 4L8, Canada
Novartis Investigative Site

Saint-Jérôme, Quebec, J7Z 5T3, Canada
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050011, China
Novartis Investigative Site

Harbin, Heilongjiang, 150081, China
Novartis Investigative Site

Zhengzhou, Henan, 450008, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310016, China
Novartis Investigative Site

Beijing, 100021, China
Novartis Investigative Site

Chongqing, 400016, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Tianjin, 300480, China
Novartis Investigative Site

Zhenjiang, 310009, China
Novartis Investigative Site

Nice, Alpes Maritimes, 06189, France
Novartis Investigative Site

Dijon, Cote D Or, 21034, France
Novartis Investigative Site

Limoges, Haute Vienne, 87000, France
Novartis Investigative Site

Saint-Cloud, Hauts De Seine, 92210, France
Novartis Investigative Site

Rennes, Ille Et Vilaine, 35062, France
Novartis Investigative Site

Grenoble, Isere, 38028, France
Novartis Investigative Site

Lyon, Rhone, 69004, France
Novartis Investigative Site

Amiens, 80000, France
Novartis Investigative Site

Angers, 49055, France
Novartis Investigative Site

Argenteuil, 95107, France
Novartis Investigative Site

Avignon, 84082, France
Novartis Investigative Site

Besançon, 25030, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Bron, 69677, France
Novartis Investigative Site

Caen, 14021, France
Novartis Investigative Site

Le Mans, 72000, France
Novartis Investigative Site

Marseille, 13008, France
Novartis Investigative Site

Montpellier, 34070, France
Novartis Investigative Site

Montpellier, 34298, France
Novartis Investigative Site

Nantes, 44202, France
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Paris, 75015, France
Novartis Investigative Site

Paris, 75231, France
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Paris, 75970, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Rouen, 76038, France
Novartis Investigative Site

Saint-Herblain, 44805, France
Novartis Investigative Site

Strasbourg, 67085, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Vandœuvre-lès-Nancy, 54519, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Ravensburg, Baden-Wurttemberg, 88212, Germany
Novartis Investigative Site

Munich, Bavaria, 80637, Germany
Novartis Investigative Site

Munich, Bavaria, 81377, Germany
Novartis Investigative Site

Munich, Bavaria, 81675, Germany
Novartis Investigative Site

Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site

Cottbus, Brandenburg, 03048, Germany
Novartis Investigative Site

Frankfurt am Main, Hesse, 60431, Germany
Novartis Investigative Site

Georgsmarienhütte, Lower Saxony, 49124, Germany
Novartis Investigative Site

Hanover, Lower Saxony, 30177, Germany
Novartis Investigative Site

Essen, North Rhine-Westphalia, 45136, Germany
Novartis Investigative Site

Mönchengladbach, North Rhine-Westphalia, 41061, Germany
Novartis Investigative Site

Velbert, North Rhine-Westphalia, 42551, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Augsburg, 86150, Germany
Novartis Investigative Site

Bad Liebenwerda, 04924, Germany
Novartis Investigative Site

Berlin, 13125, Germany
Novartis Investigative Site

Bonn, 53111, Germany
Novartis Investigative Site

Bottrop, 46236, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Hamburg, 20357, Germany
Novartis Investigative Site

Kiel, 24105, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Münster, 48149, Germany
Novartis Investigative Site

Regensburg, 93053, Germany
Novartis Investigative Site

Schweinfurt, 97422, Germany
Novartis Investigative Site

Tübingen, 72076, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Pécs, Baranya, 7623, Hungary
Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site

Zalaegerszeg, Zala County, 8900, Hungary
Novartis Investigative Site

Budapest, 1032, Hungary
Novartis Investigative Site

Budapest, 1083, Hungary
Novartis Investigative Site

Budapest, 1145, Hungary
Novartis Investigative Site

Kecskemét, 6001, Hungary
Novartis Investigative Site

Szeged, 6725, Hungary
Novartis Investigative Site

Szekszárd, 7100, Hungary
Novartis Investigative Site

Szombathely, 9700, Hungary
Novartis Investigative Site

Tatabánya, 2800, Hungary
Novartis Investigative Site

Wilton, Cork, T12 DC4A, Ireland
Novartis Investigative Site

County Limerick, V94 F858, Ireland
Novartis Investigative Site

Dublin, 533615, Ireland
Novartis Investigative Site

Dublin, D03 VX82, Ireland
Novartis Investigative Site

Dublin, DO4, Ireland
Novartis Investigative Site

Dublin, DUBLIN 9, Ireland
Novartis Investigative Site

Waterford, 48346, Ireland
Novartis Investigative Site

Ancona, AN, 60020, Italy
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Misterbianco, CT, 95045, Italy
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Palermo, PA, 90146, Italy
Novartis Investigative Site

Aviano, PN, 33081, Italy
Novartis Investigative Site

Roma, RM, 00128, Italy
Novartis Investigative Site

Candiolo, TO, 10060, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Warsaw, Ul Roentgena 5, 02-781, Poland
Novartis Investigative Site

Bialystok, 15-027, Poland
Novartis Investigative Site

Gdynia, 81-519, Poland
Novartis Investigative Site

Gliwice, 44-101, Poland
Novartis Investigative Site

Grudziądz, 86-300, Poland
Novartis Investigative Site

Krakow, 31501, Poland
Novartis Investigative Site

Lodz, 90-338, Poland
Novartis Investigative Site

Lublin, 20-090, Poland
Novartis Investigative Site

Opole, 45-054, Poland
Novartis Investigative Site

Ostrołęka, 07-410, Poland
Novartis Investigative Site

Otwock, 05-400, Poland
Novartis Investigative Site

Wieliszew, 05-135, Poland
Novartis Investigative Site

Wroclaw, 02-781, Poland
Novartis Investigative Site

Cluj-Napoca, Cluj, 400015, Romania
Novartis Investigative Site

Craiova, Dolj, 200347, Romania
Novartis Investigative Site

Craiova, Dolj, 200535, Romania
Novartis Investigative Site

Bucharest, 011171, Romania
Novartis Investigative Site

Timișoara, 300425, Romania
Novartis Investigative Site

Kazan', Russian Federation, 420029, Russia
Novartis Investigative Site

Saint Petersburg, Sankt-Peterburg, 195271, Russia
Novartis Investigative Site

Chelyabinsk, 454087, Russia
Novartis Investigative Site

Kostroma, 156005, Russia
Novartis Investigative Site

Krasnoyarsk, 660022, Russia
Novartis Investigative Site

Moscow, 111123, Russia
Novartis Investigative Site

Moscow, 115522, Russia
Novartis Investigative Site

Moscow, 143423, Russia
Novartis Investigative Site

Nizhny Novgorod, 603137, Russia
Novartis Investigative Site

Novosibirsk, 630000, Russia
Novartis Investigative Site

Obninsk, 249036, Russia
Novartis Investigative Site

Omsk, 644013, Russia
Novartis Investigative Site

Orenburg, 460021, Russia
Novartis Investigative Site

Rostov-on-Don, 344037, Russia
Novartis Investigative Site

Ryazan, 390011, Russia
Novartis Investigative Site

Saint Petersburg, 191104, Russia
Novartis Investigative Site

Saint Petersburg, 197758, Russia
Novartis Investigative Site

Saint Petersburg, 198255, Russia
Novartis Investigative Site

Tyumen, 625041, Russia
Novartis Investigative Site

Ufa, 450054, Russia
Novartis Investigative Site

Yaroslavl, 150054, Russia
Novartis Investigative Site

Seoul, Daegu, 41404, South Korea
Novartis Investigative Site

Wŏnju, Gangwon-do, 26426, South Korea
Novartis Investigative Site

Bundang Gu, Gyeonggi-do, 13620, South Korea
Novartis Investigative Site

Suwon, Gyeonggi-do, 16499, South Korea
Novartis Investigative Site

Gyeonggi-do, Korea, 10408, South Korea
Novartis Investigative Site

Incheon, Korea, 405 760, South Korea
Novartis Investigative Site

Seoul, Korea, 02841, South Korea
Novartis Investigative Site

Cheongju-si, North Chungcheong, 28644, South Korea
Novartis Investigative Site

Seoul, Yangcheon Gu, 07985, South Korea
Novartis Investigative Site

Incheon, 22332, South Korea
Novartis Investigative Site

Seongnam Gyeonggi, 463-712, South Korea
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Seoul, 06591, South Korea
Novartis Investigative Site

Ulsan, 44033, South Korea
Novartis Investigative Site

Elche, Alicante, 03203, Spain
Novartis Investigative Site

Granada, Andalusia, 18014, Spain
Novartis Investigative Site

Huelva, Andalusia, 21005, Spain
Novartis Investigative Site

Jaén, Andalusia, 23007, Spain
Novartis Investigative Site

Vitoria-Gasteiz, Araba, 01009, Spain
Novartis Investigative Site

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Manresa, Barcelona, 08242, Spain
Novartis Investigative Site

Sabadell, Barcelona, 08208, Spain
Novartis Investigative Site

Bilbao, Bizkaia, 48013, Spain
Novartis Investigative Site

Badajoz, Extremadura, 06080, Spain
Novartis Investigative Site

Cáceres, Extremadura, 10003, Spain
Novartis Investigative Site

Lugo, Galicia, 27003, Spain
Novartis Investigative Site

Donostia / San Sebastian, Gipuzkoa, 20014, Spain
Novartis Investigative Site

Fuenlabrada, Madrid, 28942, Spain
Novartis Investigative Site

El Palmar, Murcia, 30120, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Vigo, Pontevedra, 36212, Spain
Novartis Investigative Site

San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain
Novartis Investigative Site

Alicante, Valencia, 03550, Spain
Novartis Investigative Site

Valencia, Valencia, 46009, Spain
Novartis Investigative Site

A Coruña, 15006, Spain
Novartis Investigative Site

A Coruña, 15009, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Burgos, 09006, Spain
Novartis Investigative Site

Castellon, 12002, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Girona, 17007, Spain
Novartis Investigative Site

Granada, 18016, Spain
Novartis Investigative Site

Las Palmas GC, 35010, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28033, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28222, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Murcia, 30008, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Seville, 41009, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Valencia, 46014, Spain
Novartis Investigative Site

Zaragoza, 50009, Spain
Novartis Investigative Site

Changhua, 50006, Taiwan
Novartis Investigative Site

Taichung, 40447, Taiwan
Novartis Investigative Site

Taichung, 407219, Taiwan
Novartis Investigative Site

Tainan, 704302, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 103616, Taiwan
Novartis Investigative Site

Taipei, 10449, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taoyuan, 33305, Taiwan
Novartis Investigative Site

Truro, Cornwall, TR1 3LJ, United Kingdom
Novartis Investigative Site

Sutton, Surrey, SM2 5PT, United Kingdom
Novartis Investigative Site

Cardiff, CF14 2TL, United Kingdom
Novartis Investigative Site

London, NW1 2BU, United Kingdom
Novartis Investigative Site

London, SE1 9RT, United Kingdom
Novartis Investigative Site

London, SW3 6JJ, United Kingdom
Novartis Investigative Site

Nottingham, NG5 1PB, United Kingdom
Novartis Investigative Site

Oxford, OX3 7LE, United Kingdom
Novartis Investigative Site

Preston, PR2 9HT, United Kingdom
Novartis Investigative Site

Stoke-on-Trent, ST4 6QG, United Kingdom
Orlando Health Clinical Trials

Orlando, Florida, 32806, United States
Park Nicollet Institute

Saint Louis Park, Minnesota, 55416, United States
Penn State Hershey Cancer Institute

Hershey, Pennsylvania, 17033, United States
Perlmutter Cancer Centre

New York, New York, 10016, United States
Randolph Medical Associates

Asheboro, North Carolina, 27204, United States
Rocky Mountain Cancer Centers

Denver, Colorado, 80218, United States
Saint Barnabas Medical Center

Livingston, New Jersey, 07039, United States
Saint Francis Medical Center

Grand Island, Nebraska, 68803, United States
Saint Lukes Hospital of Kansas City

Kansas City, Missouri, 64111, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sharp Memorial Hospital

San Diego, California, 92123, United States
Southeastern Regional Medical Center

Newnan, Georgia, 30265, United States
Southern CA Oncology Rsrch Alliance

Los Angeles, California, 90057, United States
St Bernards Medical Center

Jonesboro, Arkansas, 72401, United States
St Vincent Frontier Cancer Center

Billings, Montana, 59102, United States
St. Jude Heritage Medical Group

Fullerton, California, 92835, United States
Stanford University Medical Center

Palo Alto, California, 94304-1509, United States
The West Clinic

Germantown, Tennessee, 38138, United States
UCLA Beverly Hills

Beverly Hills, California, 90212, United States
UCLA Burbank

Burbank, California, 91505, United States
UCLA Cancer Center Westlake Village

Westlake Village, California, 91361, United States
UCLA Hematology Oncology

Laguna Hills, California, 92653, United States
UCLA Pasadena HC Hemato Onco

Pasadena, California, 91105, United States
UCLA Porter Ranch Hemato and Onco

Porter Ranch, California, 91326, United States
UCLA Santa Monica Hematology Oncology

Santa Monica, California, 90404, United States
UCLA Valencia

Valencia, California, 91355, United States
UCSF

San Francisco, California, 94115, United States
University Of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Alabama at Birmingham-Kirklin Clinic

Birmingham, Alabama, 35294-0006, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Miami

Miami, Florida, 33136, United States
University of Michigan Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Wisconsin Paul P Carbone Comp Cancer Center

Madison, Wisconsin, 53792-6164, United States
Utah Cancer Specialists

Salt Lake City, Utah, 84106, United States
Valley Breast Care

Van Nuys, California, 91405, United States
Virginia Cancer Institute

Richmond, Virginia, 23230, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States
Yale University School Of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.